Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBR854 Cell Injection in Unresectable Locally Advanced or Metastatic Solid Tumors
NCT06001684Phase 1Completed
- Sponsor
- Imbioray
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Other Engineered Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBR854 in solid tumor, sponsored by Imbioray. Primary endpoints: Dose Limiting Toxicity at 21 days and Adverse Events at 90 days. Started Sep 2023; status: completed.
02
Drugs
IBR854
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06001684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001684.